Thus, the combination of PIN1- and CDK4-inhibitors achieves synergistic anti-tumor activity against Rb-proficient or -deficient TNBC in immune-compromised or -competent mice, with an excellent safety profile, making it a strong candidate for clinical development. This evidence concerns the gene RB1 and neoplasm.